|
About the Confirmatory Testing category -Please read before posting
|
|
1
|
745
|
March 30, 2025
|
|
EDTA-Related Nitrosamine Impurities: Two Critical Pain Points in Pharma R&D
|
|
8
|
613
|
September 7, 2026
|
|
A Derivatization Free HPLC–UV Method for Nitrite Quantification in Strongly Matrix-Affected Pharmaceutical Excipients-Pub「
|
|
3
|
121
|
September 5, 2026
|
|
In situ Formation and NNNT increase over time
|
|
4
|
150
|
September 4, 2026
|
|
Qualitative & Quantitative Analysis of Nitrosamines by FTIR
|
|
7
|
293
|
September 3, 2026
|
|
N-Nitroso Nilotinib
|
|
0
|
71
|
September 2, 2026
|
|
Is Sensitivity really the biggest challenge or is it sample preparation?
|
|
0
|
85
|
August 31, 2026
|
|
Establishing a Robust High Performance Liquid Chromatography−Ultraviolet Detection Technique for Nitrite Quantification in Pharmaceutical Excipients and Active Pharmaceutical Ingredients-Pub
|
|
0
|
119
|
August 22, 2026
|
|
A Rapid and Sensitive LC–MS/MS Method for Quantification of NDSRI in Melatonin Drug Product via Controlled In Situ Formation-Pub
|
|
0
|
116
|
August 14, 2026
|
|
N-Nitroso Metamizole Impurity C
|
|
5
|
534
|
August 11, 2026
|
|
An Analytical Quality by Design-guided method development for the quantification of N-nitroso-fluoxetine to support mitigation strategies for a fluoxetine drug product-Pub
|
|
2
|
242
|
August 8, 2026
|
|
N Nitroso Tadalfil
|
|
19
|
1433
|
August 7, 2026
|
|
Nitrosamine Control Strategy for Products within the Scope of ICH S9
|
|
5
|
331
|
August 7, 2026
|
|
Determination of Trace Nitrosamines in Plastic Pharmaceutical Packaging Materials
|
|
2
|
191
|
August 4, 2026
|
|
N-Nitroso meglumine
|
|
34
|
3001
|
August 1, 2026
|
|
N-Nitroso Desmethyl Tramadol - Standard
|
|
3
|
247
|
July 27, 2026
|
|
Nitrosamines: Mass Spectrometry-Based Analytical Procedures Criterias
|
|
12
|
4701
|
July 25, 2026
|
|
N-nitrosoproline
|
|
0
|
114
|
July 20, 2026
|
|
Determining Low PPB Levels of Nitrite in Polymeric Excipients
|
|
2
|
419
|
July 19, 2026
|
|
Trace-level LC–MS/MS quantification of two nitrosamine impurities formed from terazosin-related impurities in pharmaceutical products and greenness assessment-Pub
|
|
2
|
212
|
July 15, 2026
|
|
N-nitroso-Furosemide
|
|
4
|
759
|
July 6, 2026
|
|
N-Nitroso Desethyl Amiodarone in Amiodarone HCl Tablets by LC-MS/MS Metodu
|
|
5
|
303
|
July 6, 2026
|
|
NDBA interference on Parecoxib testing?
|
|
3
|
166
|
June 23, 2026
|
|
A Robust and Universal LC–MS/MS Method for Determination of N-Nitrosodimethylamine in Pharmaceuticals Using a C30 Column -Pub
|
|
1
|
215
|
June 22, 2026
|
|
N-Nitroso Vonoprazan impurity peak area variation observed during drug product analysis by LCMS
|
|
1
|
165
|
June 8, 2026
|
|
MS Method Development Criterias?
|
|
1
|
185
|
June 2, 2026
|
|
Understanding In Vitro Nitrosamine Formation During Sample Preparation
|
|
4
|
325
|
June 1, 2026
|
|
Solution stability of NDSRI
|
|
8
|
427
|
May 25, 2026
|
|
Development and Validation of a Trace-Level LC–MS/MS Method for the Determination of N-Nitroso Clozapine in Clozapine Drug Substance -Pub
|
|
0
|
119
|
May 20, 2026
|
|
Strategies for Mitigating In-Source Fragmentation in NDSRI Analysis using LC-MS
|
|
4
|
3010
|
May 20, 2026
|